TECNIS Eyhance IOL reaches 10 million-implant milestone

Johnson & Johnson’s TECNIS Eyhance intraocular lens (IOL) has been implanted in more than 10 million eyes globally, according to company news release issued during the ASCRS 2026 meeting.

The TECNIS Eyhance IOL, described as the first enhanced monofocal IOL, is positioned within a category designed to provide intermediate vision while maintaining distance clarity. The company stated that the lens is supported by a large body of clinical evidence and has seen continued adoption among cataract surgeons.

“Reaching over 10 million implants is not just a volume milestone—It is validation that TECNIS Eyhance IOL delivers consistent, real-world outcomes at scale,” said Paul Lisenby, Global Head of R&D, Vision, Johnson & Johnson. “That level of adoption reflects years of clinical evidence, surgeon trust, and performance under everyday visual conditions.”

Since its introduction in 2019, the TECNIS Eyhance IOL has been designed to slightly extend depth of focus while maintaining distance vision quality and image contrast. The company stated that, compared with other options, the lens is supported by published clinical evidence across a range of patient populations and practice settings.

According to the release, clinical data include more than 26 studies evaluating contrast sensitivity, including some conducted in low-light conditions; 48 studies assessing intermediate vision; and 20 studies reporting low rates of visual disturbances such as halos, starbursts, and glare.

The TECNIS Eyhance IOL is part of the TECNIS platform, which Johnson & Johnson said has been used in ophthalmology for more than 25 years. The portfolio also includes the TECNIS PureSee IOL, a refractive extended depth of focus lens, and the TECNIS Odyssey IOL, described as a full visual range IOL. The company noted it plans to present new data on these lenses at ASCRS 2026.